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While mechanisms of resistance to major antifungal agents have been characterized in Candida albicans,
little is known about the evolutionary trajectories during the emergence of drug resistance. Here, we examined
the evolutionary dynamics of C. albicans that evolved in vitro in the presence or absence of fluconazole using
the visualizing evolution in real-time (VERT) method, a novel experimental approach that facilitates the
systematic isolation of adaptive mutants that arise in the population. We found an increase in the frequency
of adaptive events in the presence of fluconazole compared to the no-drug controls. Analysis of the evolutionary
dynamics revealed that mutations that led to increased drug resistance appeared frequently and that mutants
with increased levels of resistance arose in independent lineages. Interestingly, most adaptive mutants with
increased fitness in the presence of the drug did not exhibit a significant fitness decrease in the absence of the
drug, supporting the idea that rapid resistance can arise from mutations in strains maintained in the
population prior to exposure to the drug.
The emergence of antimicrobial drug resistance in patho-
gens is a process of adaptive evolution, generally as a result of
genetic mutations. Depending on the size of the population,
the rate of mutation, and the relative fitness coefficients, the
population may be heterogeneous, consisting of multiple resis-
tant genotypes competing for expansion in a process called
“clonal interference” (10, 12). Determining the evolutionary
dynamics during adaptation is important for understanding the
fundamental principles underlying how eukaryotic microbes
evolve resistance to antimicrobial agents, a process that differs
from that in bacteria because it is unlikely to involve horizontal
gene transfer (1, 6).
It is important to understand the frequencies with which
adaptive mutants arise and expand, the evolutionary trajecto-
ries (the order of occurrence of adaptive mutations), and the
potential convergence or divergence in the adaptive mecha-
nisms between parallel populations in order to better appreci-
ate how drug resistance can emerge in pathogens growing
within the host. For example, knowledge of the frequency and
order in which drug-resistant mutants arise in the population
and whether the early-arising resistance mechanisms play a
role in the level of drug resistance ultimately reached in the
population can be used to predict the likely trajectory of a
clinical infection and to develop appropriate therapeutic strat-
egies.
Candida albicans is the fourth most common cause of nos-
ocomial infections, resulting in rates of mortality in U.S. hos-
pitals that approach 50% (23, 24, 44). Emergence of resistance
to almost all major antifungal agents used in treating C. albi-
cans infections has been reported (15, 22, 29). Among the
existing classes of antifungal drugs, azoles are the most com-
monly used, due to their low toxicity and their oral availability.
The fact that they are fungistatic rather than fungicidal pro-
vides a clear opportunity for the evolution of drug resistance
during long periods of prophylactic treatment (25).
The mechanisms of resistance to azole drugs have been
studied extensively (18, 19, 21, 27, 28, 32, 36, 37, 40, 42, 43).
However, a large percentage (50%) of drug-resistant clinical
isolates from a reported collection have unknown mechanisms
of resistance (40). In C. albicans, resistance has arisen both in
vitro and in vivo and includes point mutations, loss of heterozy-
gosity, and/or gross chromosomal-rearrangement mechanisms,
(32, 34, 35). Studies of drug-resistant isolates from patients
during the course of treatment, as well as from long-term
laboratory evolution experiments, suggest that evolving popu-
lations are heterogeneous, include multiple resistance mecha-
nisms (9, 35, 38, 39), and likely involve complex population
dynamics. For example, in a series of 9 C. albicans isolates from
a bone marrow transplant patient undergoing antifungal drug
treatments, multiple resistance mechanisms were present and
competing (34), further highlighting the need to understand
the dynamics during the emergence of drug resistance.
Here, we report the first study to monitor the rise and
expansion of adaptive events in C. albicans during in vitro
evolution in continuous cultures under increasing concentra-
tions of fluconazole. We used the visualizing evolution in real-
time (VERT) approach, which was originally developed for
analyzing evolution in the model eukaryote Saccharomyces
cerevisiae (14). In VERT, a set of isogenic strains differing only
in their expression of different fluorescent proteins (FP) is used
to visualize when adaptive events occur (the rise and expansion
of adaptive mutants), to determine how frequently they occur,
and to facilitate the identification and isolation of adaptive
mutants from the population. The evolutionary dynamics indi-
cate that adaptive events occur more frequently in the pres-
ence of the drug than in the control populations that evolved in
the absence of the drug. Adaptive clones isolated from each of
the observed adaptive events and relative fitness coefficient
measurements were used to estimate the fitness costs associ-
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ated with increases in the level of drug resistance. Importantly,
increases in drug resistance were not necessarily accompanied
by significant fitness costs and in some cases were accompanied
by fitness increases.
MATERIALS AND METHODS
Strains. All strains used in this work are isogenic derivatives of the C. albicans
strain SC5314. Three different fluorescent cassettes, each containing a NAT1
marker and a fluorescent protein (either red fluorescent protein [RFP], green
fluorescent protein [GFP], or yellow fluorescent protein [YFP]), were amplified
by PCR from plasmids pMG2261, pMG2120, and pMG2263, respectively, using
two different sets of primers. The primers for PCR amplifying GFP and YFP
cassettes were 5-GAG AAT CGA AGA AGA ATT AGG TTC TGA AGC TAT
CTA CGC TGG TAA AGA TTT CCA AAA GGC TTC TCA ATT GGG TGG
TGG TTC TAA AGG TGA AGA ATT ATT-3 and 5-TTT AAT TAG TTC
ATA TAT TCA AGA TGT TCC TAT AAA AGA AAA AAA AAG CAC CAG
CTT TTT TTT ATT TAA TCG TAA AAC GAC GGC CAG TGA ATT C-3.
The primers for amplifying the RFP cassette were 5-GAG AAT CGA AGA
AGA ATT AGG TTC TGA AGC TAT CTA CGC TGG TAA AGA TTT CCA
AAA GGC TTC TCA ATT GGG TGG TGG TGA TAA CAC TGA AGA TGT
TAT T-3 and 5-TTT AAT TAG TTC ATA TAT TCA AGA TGT TCC TAT
AAA AGA AAA AAA AAG CAC CAG CTT TTT TTT ATT TAA TCG TAA
AAC GAC GGC CAG TGA ATT C-3. The resulting PCR products were then
transformed into strain SC5314 to form a translational fusion of fluorescent
cassettes to the 3 end of the ENO1 gene in the chromosome by homologous
recombination. Transformants were selected on yeast extract-peptone-dextrose
plus adenine (YPAD) agar plates with nourseothricin (400 g/ml), and the
fluorescence of each strain was confirmed by microscopy.
The strains were grown in yeast nitrogen base (YNB) without amino acids
supplemented with 0.5% (wt/vol) ammonium sulfate and 2% (wt/vol) D-glucose
unless otherwise specified.
Laboratory evolution experiments. Cells expressing each fluorescent protein
(GFP, YFP, or RFP) were mixed together in approximately equal numbers (as
confirmed by flow cytometry) at the start of parallel chemostat (30 ml each)
evolution experiments in YNB supplemented with 0.5% (wt/vol) ammonium
sulfate and 0.2% dextrose (the limiting nutrient) with or without fluconazole.
The populations evolved at steady state at 30°C at a dilution rate (D) of 0.2
h1. In chemostat experiments, the generation time is determined by the dilution
rate. Using a dilution rate of 0.2 h1, the generation time is calculated as
ln(2)/0.2, or 3.5 h/generation. Two parallel series of evolution experiments were
conducted; each series contained one control population (no fluconazole) and
one population exposed to stepwise increases of fluconazole, starting with 0.25
g per ml and increasing the concentration by 4-fold every 50 to 70 generations.
Samples were taken every 7 to 14 generations, and a portion (1.5 ml) of the cells
were frozen in 17% glycerol for future analysis. Cell concentrations were mea-
sured using a hemocytometer, and the relative proportions of the three subpopu-
lations (GFP, YFP, and RFP) were measured using a FACScan flow cytometer
(BD Biosciences, San Jose, CA).
Isolation of adaptive mutants. At the conclusion of the evolution experiment,
we identified the time point samples likely to have a substantial fraction of an
adaptive clone in one of the fluorescently marked subpopulations, based on the
dynamics of the relative subpopulation sizes. Specifically, we identified the time
point sample in which an expanding colored FP subpopulation appeared to reach
its maximum proportion of the population. Population samples from the gener-
ation at which the expanding subpopulation reached a maximum proportion
were plated on YNB plates. Using a Dark Reader (Clare Chemical), which can
distinguish GFP-, YFP-, and RFP-expressing cells, at least seven isolates express-
ing the colored fluorescent protein of the expanding subpopulation were picked
for fitness measurements. For all isolates from the same adaptive event, we
performed pairwise competition experiments by growing each isolate in contin-
uous culture together with the previous adaptive mutant (for the first observed
adaptive event, the isolates were individually competed against the parental
strain of a different FP). Figure S1 in the supplemental material shows the flow
of the process. The experiments were carried out in the presence of the same
concentration of fluconazole used during the evolution of those isolates. Of the
seven or more clones tested from each observed adaptive event, the clone with
the highest fitness coefficient was chosen as the adaptive clone for that adaptive
event, except in cases where multiple isolates exhibited similar fitness coeffi-
cients. In those cases, an arbitrary isolate was chosen from the fittest group.
Pairwise competition experiments. Chemostat experiments in YNB with 0.2%
dextrose and 0.5% (wt/vol) ammonium sulfate and in the presence or absence of
fluconazole were initiated with approximately equal numbers of the two clones to
be competed (each carrying a different FP marker). The pairwise competition
experiments were conducted at 30°C with a dilution rate of 0.2 h1. Samples
were taken every 1 to 5 generations, and the relative proportions of each of the
two clones were measured using flow cytometry. The data were plotted on a
linear scale with ln[x/(1  x)] versus t, where x is the fraction of the sample clone
and t is generations. The relative fitness coefficient was determined from the
slope of the linear region of the curve using linear regression analysis. For
statistical analysis, the relative fitness coefficients between pairs of the fluorescently
labeled parental strains were measured either in the absence of fluconazole or in the
presence of 0.25 g/ml of fluconazole. A minimum of three biological replicates
were performed for each pairwise competition experiment. A Student t test was used
to determine whether the relative fitness coefficients measured for the adaptive
mutants were statistically significant (P value cutoff, 0.05).
MIC measurements. The fluconazole MIC for each isolated adaptive mutant
was determined with an Etest strip according to the manufacturer’s instructions
(bioMe´rieux SA, France). The highest MIC value from 3 biological replicates
was reported.
Stability analysis of adaptive mutants. One of the parent strains (KKCa-14)
and all isolated adaptive mutants from the DP-1 and DP-2 populations under-
went stability tests in the absence of fluconazole. The strains were first plated on
YNB plates supplemented with 2% dextrose, and a single colony was picked up
and transferred into fresh YNB broth. Five microliters of cell culture for each
strain was inoculated into 5 ml fresh YNB broth to make a 1,000-fold dilution
and then was incubated at 30°C for 24 h. The transfer was repeated for two more
days (for a total of 30 generations). The optical density of the cell culture was
measured at 600 nm before each transfer. MIC measurements were performed
for each strain to test the stability of the drug resistance after long-term incu-
bation in serial batch transfer in the absence of the drug.
CHEF karyotype analysis. Preparation of cells for contour-clamped homoge-
neous electric field (CHEF) karyotype analysis was performed as described
previously (31). Whole-chromosome separation was performed on a Bio-Rad
CHEF-DR III with the following program: 60- to 120-s switch, 6 V/cm, 120°
angle for 36 h, followed by a 120- to 300-s switch, 4.5 V/cm, 120° angle for 12 h.
SfiI digestion of CHEF gel plugs was performed using the following procedure.
A portion of whole-chromosome CHEF plugs were washed twice for 10 min each
time in 1 ml of 10 mM Tris (pH 8.0), 1 mM EDTA (TE buffer) and then
incubated in 1 ml of TE buffer containing 0.1 mM phenylmethylsulfonyl fluoride
for 10 min. The plugs were washed twice as before and incubated in 500 l of SfiI
restriction enzyme buffer containing bovine serum albumin (BSA) at 100 g/ml
for 15 min, and 40 units of SfiI enzyme was added. The SfiI-treated plugs were
then incubated overnight at 50°C, washed in 100 mM EDTA (pH 8.0), added to
a 1% Megabase agarose gel (Bio-Rad, Hercules, CA) in 0.5 TBE buffer (45
mM Tris, 45 mM boric acid, 1 mM EDTA), and separated as previously de-
scribed (35).
Ploidy analysis. Strain ploidy was examined by flow cytometry. C. albicans
strains were grown to log phase, and 4  106 cells were collected in a round-
bottom microtiter plate by centrifugation. The pellets were resuspended in 20 l
of 50 mM Tris, pH 8, 50 mM EDTA (50/50 TE); 180 l of 95% ethanol was
added dropwise, and the suspensions were stored overnight at 20°C. The
ethanol-fixed cell pellets were washed twice with 200 l of 50/50 TE, resuspended
in 200 l of RNase A at 500 g/ml in 50/50 TE, and incubated for 2 h at 37°C.
The cells were centrifuged again, and the pellets were incubated in 200 l of 1
mg/ml proteinase K in 50/50 TE for 2 h at 37°C. The cells were centrifuged again
and washed in 50/50 TE, and the pellets were resuspended in 50 l of Sybr green
I (1:85 dilution; Invitrogen, Carlsbad, CA) in 50/50 TE and incubated overnight
in the dark. Finally, the cells were centrifuged, the pellets were resuspended in
700 l 50/50 TE, and ploidy was detected and analyzed on a FACScaliber flow
cytometer (BD Biosciences, San Jose, CA).
RESULTS
Adaptive evolution in the presence of fluconazole. Two sets
of parallel populations of C. albicans were allowed to evolve
either in the absence (control populations, CP-1 and CP-2) or
in the presence (DP-1 and DP-2) of increasing concentrations
of fluconazole. The VERT system was used to follow the evo-
lutionary dynamics of three subpopulations within each paral-
lel population. At the start of the VERT experiment, the pop-
ulations were initiated with approximately equal numbers of
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each FP cell type. The relative proportions of each FP subpop-
ulation were measured using flow cytometry. For the flucona-
zole-exposed populations (DP-1 and DP-2), the concentration
of fluconazole at the start of the experiment was 0.25 g/ml,
which is equal to twice the MIC of the parental strains. At
generation 64, the fluconazole concentration had increased to
1 g/ml, and at generation 112, it had further increased to 4
g/ml. The evolutionary dynamics for all 4 populations over
approximately 170 generations are shown in Fig. 1.
An observed expansion of a particular FP subpopulation is
indicative of an adaptive event within that subpopulation, and
clones that were likely to be responsible for the observed
expansions were isolated and named according to the popula-
tion from which they were isolated. For example, clone CP-
1-M1 was the adaptive mutant isolated from the first observed
expansion (M1) from the CP-1 population. Based on the evo-
lutionary dynamics observed, an adaptive event occurred every
20 to 50 generations in the controls and every 10 to 40
generations in the fluconazole-exposed populations. Thus, the
number of adaptive events observed over 170 generations
was significantly higher in the populations exposed to drug
than in those not exposed to drug, with approximately 7 and 10
adaptive events observed in the two fluconazole-exposed pop-
ulations and 3 and 4 adaptive events observed in the control
populations.
Dynamics of evolution in the presence of fluconazole. We
expected that exposure of an expanding subpopulation to in-
creased fluconazole concentrations would result in continued
expansion of that FP subpopulation, as the most competitive
clone is most likely present within the subpopulation that is
expanding. Indeed, this expected trend was observed in the
DP-1 population. Upon the first increase in the fluconazole
concentration, the YFP subpopulation, which started expand-
ing at approximately generation 58, continued to expand fol-
lowing the increase in the drug concentration at generation 64.
In addition, the RFP subpopulation began to expand at this
time point, suggesting that an adaptive clone arose in this
subpopulation, as well. Indeed, the adaptive mutant isolated
after the first increase in the fluconazole concentration (DP-
1-M2) showed increased fitness compared to both the previous
adaptive mutant (DP-1-M1) and the parental strain (KKCa-
20) in the presence of the drug (Fig. 2 and 3 and Tables 1 and
2), despite the fact that the MIC for fluconazole was 0.38 g/ml
for both DP-1-M1 and DP-1-M2. Upon the second increase in
the fluconazole concentration, at generation 112, the expand-
ing YFP subpopulation again continued to expand as expected,
suggesting that the expanding subpopulations prior to each
increase in the drug concentration were composed of the most
drug-resistant mutants. However, the isolated adaptive mutant
after the second increase in the drug concentration (DP-1-M4)
FIG. 1. Evolutionary dynamics of experimental populations evolved either in the absence (CP-1 population [A] and CP-2 population [B]) or
presence (DP-1 population [C] and DP-2 population [D]) of fluconazole. The colored bars represent the relative fractions of each colored
subpopulation, RFP (red), GFP (green), and YFP (yellow), as determined using fluorescence-activated cell sorting (FACS). FLU, concentration
of fluconazole in the feed. The subpopulations from which the adaptive mutants were isolated are numbered (details are in Table 1).
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was not more fit than the previous adaptive mutant (DP-1-M3)
in the presence of fluconazole but was slightly more fit in the
absence of the drug.
Interestingly, we did not observe the same trend in the DP-2
population. After each of the stepwise increases in the flucona-
zole concentration, a different FP subpopulation started to
expand. One possibility to account for this observation is that
a more drug-resistant mutant was already present in the sub-
population that started expanding after the increase in the
drug concentration, but it was present at a low frequency and
thus was more difficult to observe (see below for further dis-
cussion).
Relative fitness coefficients in the presence and absence of
drug. The observed adaptive events and the colored FP corre-
sponding to each adaptive expanding subpopulation at the
generation in which it reached its maximum proportion of the
population are illustrated in Fig. 1. Adaptive mutants (listed in
Table 1) were isolated from each of the observed adaptive
events (see Materials and Methods for details). The fitness
coefficient of each isolated adaptive clone was determined by
competing the isolate against the previous adaptive clone (for
all isolated adaptive mutants) and the parental strain of a
different color (for adaptive mutants isolated from the DP-1
and DP-2 populations), either in the presence (for the flucona-
zole-exposed populations) or in the absence (for both flucona-
zole-exposed and no-drug control populations) of drug (Fig. 2
and 3 and Tables 1 and 2). While not all isolated adaptive
mutants from the fluconazole-exposed populations exhib-
ited an increase in fitness compared to the previous adaptive
mutants, all of them showed increases in fitness compared to
FIG. 2. Relative fitness coefficients of adaptive mutants isolated
from the fluconazole-exposed populations compared with the previous
adaptive mutant, DP-1 (A) and DP-2 (B), in the presence of flucona-
zole (hatched bars), measured at the drug concentration indicated
by the solid line, or without fluconazole (solid bars). The data
shown are the averages and standard deviations (SD) of a minimum
of 3 biological replicates. The asterisks indicate that the relative
fitness difference measured in the adaptive strains is statistically
significant (P  0.05, using an unpaired Student t test with unequal
variance). The dashed line indicates the measured MIC of each
adaptive mutant.
FIG. 3. Relative fitness coefficients of adaptive mutants isolated
from fluconazole-exposed populations compared with the parental
strain (different FP), DP-1 (A) and DP-2 (B), in the presence of
0.25 g/ml of fluconazole (hatched bars) or without fluconazole
(solid bars). The data shown are the averages and SD of a minimum
of 3 biological replicates. The asterisks indicate that the relative
fitness difference measured in the adaptive strains is statistically
significant (P  0.05, using an unpaired Student t test with unequal
variance).
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the parental strain in the presence of fluconazole (Fig. 3 and
Table 2).
Interestingly, for most of the adaptive clones isolated from
the fluconazole-exposed populations, increases in the relative
fitness coefficient in the presence of fluconazole were not ac-
companied by significant decreases in fitness in the absence of
the drug. This was especially evident in the isolated adaptive
mutants from the DP-2 population, where most mutants ex-
hibited an increase in the relative fitness coefficient compared
to the parental strain in the absence of the drug, suggesting
that there was no fitness cost associated with the increase in
drug resistance (Fig. 3 and Table 2). Furthermore, for most of
the adaptive clones, there was no fitness cost associated with
increases in the MIC (Fig. 2 and Table 1).
Chromosomal rearrangements. Because aneuploidy has
been associated with the acquisition of fluconazole resistance
in a subset of C. albicans isolates (32, 34), we next asked if any
of the adaptive mutants exhibited obvious signs of altered
ploidy, using flow cytometry to measure the DNA content
(Table 1). The majority of the adaptive mutants appeared to be
diploids (2N). However, there were two exceptions: strain CP-
2-M2, isolated from generation 125 of the control population,
had an 4N genome content, suggesting that it is a tetraploid;
strain DP-1-M6, isolated from generation 146 of the flucona-
TABLE 2. Relative fitness coefficients for isolated adaptive mutants
compared to the parental isolate used to initiate the culture
Adaptive
event Strain
No drug FLUb
Relative
fitnessa/
generation
P
valuea
Relative
fitnessa/
generation
P
valuea
8 DP-1-M1 0.02  0.1 0.74 0.58  0.13 0.01
9 DP-1-M2 0.03  0.01 0.05 0.51  0.1 0.01
10 DP-1-M3 0.07  0.04 0.08 0.71  0.13 0.01
11 DP-1-M4 0.11  0.06 0.07 0.22  0.03 0.00
12 DP-1-M5 0.1  0.02 0.01 0.68  0.06 0.00
13 DP-1-M6 0.02  0.07 0.50 0.63  0.08 0.00
14 DP-1-M7 0.05  0.02 0.04 0.52  0.05 0.00
15 DP-2-M1 0.02  0.07 0.63 0.42  0.08 0.00
16 DP-2-M2 0.03  0.01 0.00 0.61  0.01 0.00
17 DP-2-M3 0.11  0.03 0.03 0.62  0.08 0.00
18 DP-2-M4 0.23  0.03 0.01 0.41  0.08 0.01
19 DP-2-M5 0.12  0.02 0.01 0.67  0.08 0.03
20 DP-2-M6 0.15  0.06 0.05 0.61  0.05 0.00
21 DP-2-M7 0.13  0.03 0.01 0.52  0.13 0.02
22 DP-2-M8 0.06  0.04 0.08 0.49  0.01 0.00
23 DP-2-M9 0.19  0.02 0.00 0.47  0.1 0.01
24 DP-2-M10 0.02  0.01 0.03 0.51  0.04 0.00
a Relative to the parental strain of a different color.
b FLU, fluconazole.
TABLE 1. Adaptive mutants isolated from both fluconazole-exposed (FLU) and control populations
Adaptive event Strain Colora FLU(g/ml)b
No. of
generationsc
No drug FLU
MIC
(g/ml) PloidyRelative fitnessd/
generation
P
valued
Relative fitnessd/
generation P value
d
Parental KKCa-14 RFP 0.125 2N
Parental KKCa-17 GFP 0.125 2N
Parental KKCa-20 YFP 0.125 2N
1 CP-1-M1 RFP 0 64 0.16  0.1 0.05 NAe NA 2N
2 CP-1-M2 YFP 0 70 0.05  0.01 0.00 NA NA 2N
3 CP-1-M3 GFP 0 106 0.15  0.02 0.00 NA NA 2N
4 CP-1-M4 RFP 0 158 0.24  0.14 0.02 NA NA 2N
5 CP-2-M1 GFP 0 76 0.3  0.02 0.00 NA NA 2N
6 CP-2-M2 YFP 0 125 0.11  0.09 0.09 NA NA 4N
7 CP-2-M3 RFP 0 172 0.09  0.11 0.12 NA NA 2N
8 DP-1-M1 RFP 0.25 58 0.02  0.1 0.74 0.58  0.13 0.01 0.38 2N
9 DP-1-M2 YFP 1 76 0.03  0.1 0.53 0.5  0.05 0.00 0.38 2N
10 DP-1-M3 RFP 1 93 0.02  0.01 0.00 0.27  0.06 0.01 1 2N
11 DP-1-M4 YFP 4 125 0.04  0.02 0.02 0.03  0.25 0.88 1 2N
12 DP-1-M5 GFP 4 134 0.21  0.02 0.00 0.55  0.23 0.05 1.5 2N
13 DP-1-M6 RFP 4 146 0.09  0.03 0.03 0.17  0.08 0.02 2 3N
14 DP-1-M7 YFP 4 172 0.13  0.01 0.00 0.35  0.16 0.06 3 2N
15 DP-2-M1 RFP 0.25 31 0  0.07 0.95 0.42  0.08 0.00 0.75 2N
16 DP-2-M2 GFP 0.25 47 0.11  0.08 0.08 0.12  0.11 0.20 0.5 2N
17 DP-2-M3 RFP 0.25 52 0.16  0.1 0.11 0.16  0.15 0.13 1 2N
18 DP-2-M4 GFP 0.25 64 0.14  0.02 0.00 0.32  0.03 0.00 0.19 2N
19 DP-2-M5 YFP 1 76 0.15  0.04 0.02 0.68  0.34 0.03 0.5 2N
20 DP-2-M6 RFP 1 106 0.06  0.03 0.04 0.31  0.20 0.12 2 2N
21 DP-2-M7 GFP 1 112 0.02  0 0.01 0.26  0.15 0.03 0.5 2N
22 DP-2-M8 RFP 4 125 0.02  0.01 0.01 0.49  0.15 0.03 1 2N
23 DP-2-M9 GFP 4 153 0.1  0.02 0.01 0.4  0.06 0.00 0.25 2N
24 DP-2-M10 RFP 4 172 0.11  0.04 0.04 0.29  0.04 0.00 8 2N
a Fluorescent marker.
b Fluconazole concentration in the feed.
c Generation from which the strain was isolated.
d Relative to previous adaptive mutant.
e NA, not applicable.
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zole-exposed population, had an 3N genome content, sug-
gesting that it may be triploid or multiply aneuploid.
To examine if there were any obvious gross chromosomal
rearrangements in the isolated adaptive mutants, we per-
formed CHEF gel analysis (see Fig. S2 in the supplemental
material). Alterations in the mobility of chromosome 6 (Chr6)
and -7 are often detected and are likely due to alterations in
the lengths of the major repeat sequence tracts (16). No alter-
ations in the larger bands were observed, and no ectopic bands
were evident. Analysis of genomic DNA digested with SfiI,
which digests the genome into 2 or 3 resolvable bands per
chromosome, detected new bands in two independent lineages:
strains DP-1-M6 (RFP) and DP-1-M7 (GFP) (Fig. 4). To iden-
tify the DNA present in each of these bands, they were excised
from the gel and hybridized to microarrays of C. albicans open
reading frame (ORFs) (11, 35). In both cases, hybridization
detected a region of ChrR spanning the approximate coordi-
nates 1,353 to 1,907 kb. This SfiI fragment begins at a major
repeat sequence (MRS), includes the centromere (CENR),
and ends at an SfiI site just past the rDNA repeats. The most
likely explanation is that the presence of the new band was due
to an alteration in the lengths of the rDNA repeats. Thus, we
did not detect any major genome rearrangements spanning
nonrepetitive regions of the genome (33). In addition, we did
not detect the appearance of chromosome 5L isochromosome
[i(5L)] (M. McClellan and J. Berman, data not shown).
Stability of increased drug resistance. Increased fluconazole
resistance in the adaptive mutants could arise from transient
physiological changes or more stable genetic changes. To ask if
the increased drug resistance was stable, adaptive mutants
isolated from the DP-1 and DP-2 populations were subjected
to serial transfer for approximately 30 generations in the ab-
sence of fluconazole, and then the MICs of the transferred
isolates were compared to the MICs of the original mutants.
Importantly, the MIC values of all of the adaptive mutants
tested did not decrease following the nonselective serial trans-
fer and always remained higher than the MIC values of the
parental strain, suggesting that the drug resistance is stable for
a period of at least 30 generations (Fig. 5) and is likely due to
a genetic change.
DISCUSSION
Fitness cost of drug resistance. The fitness effect associated
with a resistance mutation plays a key role in determining
whether the resistant genotype can be maintained and whether
it has the possibility of becoming dominant in the population
(3, 4). In most bacteria, a drug-resistant phenotype is acquired
via horizontal gene transfer and is usually accompanied by a
fitness cost in the absence of the drug. Thus, it is expected that,
in the absence of drug, the proportion of the population rep-
resented by the drug-resistant subpopulation will decrease or
be eliminated from the population. Alternatively, further evo-
lution in the absence of drug can give rise to compensatory
mutations, resulting in improved fitness of drug-resistant mu-
tants (4, 17, 20, 30). In fungal cells, where resistance is acquired
via changes in the genome rather than via horizontal gene
transfer, the situation appears to be more complex.
Most of the adaptive mutants that evolved in the presence of
drug showed no significant decrease in relative fitness in the
absence of the drug. This is similar to other studies in C.
albicans, where the acquisition of antifungal drug resistance
was accompanied by no immediate fitness cost (2, 7). In fact,
several adaptive mutants isolated from the DP-2 population
exhibited increases in relative fitness compared to the parental
strain in the absence of drug (Fig. 3 and Table 2). In one study,
the initial fitness costs that were likely associated with antifun-
gal drug resistance in one population decreased upon further
evolution (8). In another study, the drug resistance acquired by
C. albicans after evolution in fluconazole was unstable and
reverted to the drug-susceptible phenotype after serial pas-
sage in the absence of the drug (5). The reversion to a
drug-susceptible phenotype in the absence of the drug sug-
gests that some mechanisms of drug resistance are associ-
ated with a fitness cost.
The different degrees of reversion of this resistance are
likely due to the specific mechanism that confers resistance, as
FIG. 4. Detection of genome rearrangements using SfiI-digested
chromosomes separated by CHEF gel electrophoresis. The arrow in-
dicates a novel band migrating in strains DP-1-M6 and DP-1-M7.
Subsequent analysis indicated that this band corresponds to ChrR and
is hypothesized to include altered numbers of rDNA repeats (Mc-
Clellan and Berman, data not shown).
FIG. 5. Stability of drug resistance. Shown are the MIC values for
one of the parental strains and all of the isolated adaptive mutants
from the fluconazole-exposed populations before and after serial pas-
sage in the absence of the drug for more than 30 generations.
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well as to the genetic changes that gave rise to it. For example,
increased levels of efflux pump activity likely incur a fitness cost
because the cell expends energy in removing not only drug, but
also nutrients, from the cell. Alternatively, a minor change in
the conformation of an enzyme involved in sterol biosynthesis
may not have much effect on the efficiency of the process in the
absence of drug. Similarly, an aneuploidy that confers drug
resistance, such as i(5L), may be acquired (and lost) rapidly via
mitotic nondisjunction, irrespective of whether it incurs a large
fitness cost. In contrast, once point mutations are acquired
(which is a lower-frequency event), reversion of these muta-
tions may require precise changes that also arise less fre-
quently.
The appearance of adaptive mutants that had large increases
in ploidy is of particular interest, as is the fact that these ploidy
differences did not appear to persist in the populations. DP-1-
M6, an isolate from a fluconazole-exposed population, has an
3N ploidy and did not exhibit a decrease in fitness compared
with the parental strain but did show a decrease in relative
fitness in the presence of the drug compared to the previous
adaptive mutant from the same population. The other event
appeared in the no-drug control population, where it is impor-
tant to note that cells were maintained under limiting glucose,
which is considered a stress condition (11). Importantly, we did
not detect the appearance of i(5L) (McClellan and Berman,
data not shown), a rearrangement that causes fluconazole re-
sistance (34). The only detectable genome rearrangements
were most likely due to alterations in the lengths of the rDNA
repeat tracts on ChrR and alterations in the lengths of MRS
tracts on Chr6 and -7. The lack of observed gross chromosomal
rearrangements that are generally associated with increased
fluconazole resistance and the stability of the increased drug
resistance in the absence of the drug suggest that the resistance
mechanisms are due to single nucleotide polymorphisms
(SNPs) and other stable genome rearrangements that are not
detectable by CHEF analyses (33). It is possible that some of
the beneficial mutations were already present in the initial
colony or during the batch growth phase prior to initiation of
the continuous-culture experiments (13) and are thus not a
result of the selection process in the chemostats. However,
with the use of VERT, we were able to identify multiple adap-
tive events that occurred in different fluorescent subpopula-
tions during the course of the laboratory evolution, and thus, it
is unlikely that all the beneficial mutations were already pres-
ent prior to the start of evolution. Future work will use whole-
genome transcriptional profiling and resequencing to identify
all genome changes in the isolated adaptive mutants and the
parental strains, allowing us to address the possibility of the
issue mentioned above and to shed light on their resistance
mechanisms.
Relationship between the evolutionary dynamics and rela-
tive fitness of adaptive mutants. Theoretically, each adaptive
mutant isolated from an observed adaptive event should be
fitter than the adaptive mutant isolated from the previous
expanding subpopulation (e.g., M3 should be fitter than M2
from the same population). Consistent with this, most of the
isolated adaptive mutants exhibit increased fitness compared
with the previous adaptive mutant. Nonetheless, some excep-
tions appeared: adaptive mutants DP-1-M6 (generation 146),
DP-2-M4 (generation 64), and DP-2-M7 (generation 112) ex-
hibited negative relative fitness coefficients in the presence of
the drug, suggesting that they were less drug resistant than the
previous adaptive mutant. MIC measurements confirmed this
for DP-2-M4 and DP-2-M7 but not for DP-1-M6. Here, we
offer some potential explanations for these exceptions. The
observed expansion leading to the isolation of the DP-2-M7
was likely due to noise in the measurements rather than to a
bona fide adaptive event, since the expansion occurred during
a quasi-steady state for the relative proportions of the three FP
subpopulations from generation 100 to generation 112 and
only one time point exhibited that increase in the GFP sub-
population at generation 112. The relative fitness coefficient
measurements further supported this idea: this GFP isolate
was less fit than the previous adaptive mutant (DP-2-M6 iso-
lated from the RFP subpopulation) in the presence of drug.
Alternatively, complex interactions in the population that can-
not be detected with the 3-color VERT analysis could contrib-
ute to the transient increase in the GFP population. In con-
trast, the green expansion that led to the isolation of DP-2-M4
was clearly an adaptive event, based on the population dynam-
ics. However, none of the 8 clones isolated from the green
subpopulation at generation 64 from the DP-2 population
showed an increase in fitness relative to DP-2-M3. Based on
the rate of expansion of the green subpopulation, it is unlikely
that the expanding adaptive mutant was in a small proportion
of the population. Thus, either the actual adaptive mutant
responsible for the observed expansion was not present among
the 8 colonies picked or the condition used for the relative
fitness coefficient measurements was not able to recapitulate
the relative fitness benefit of DP-2-M4 during the evolution
experiment. Even though the DP-2-M4 and DP-2-M7 clones
may not have been responsible for the expansion of the colored
subpopulations, both are adaptive mutants, as they had in-
creased fitness compared to the parental strain in the presence
of fluconazole.
We expected that the expanding subpopulation prior to each
stepwise increase in the fluconazole concentration would con-
tinue expanding, as it likely contained the fittest mutant in the
population at that time point. However, this trend was not
observed in the DP-2 population; rather, after each stepwise
increase in the fluconazole concentration, a different FP sub-
population began expanding. For example, prior to generation
64, the GFP subpopulation was expanding, but after the in-
crease in the drug concentration, the RFP and YFP subpopu-
lations started to expand, and the YFP adaptive mutant iso-
lated (DP-2-M5) was indeed more drug resistant than the GFP
adaptive mutant isolated prior to the drug increase (DP-2-M4).
One explanation for this observation is that the adaptive mu-
tant, DP-2-M5, may have been present in the YFP subpopu-
lation prior to generation 64 but was at a low enough frequency
or was not expanding fast enough to result in an observed
expansion of the YFP subpopulation prior to the increase in
the fluconazole concentration. This further demonstrates the
effects of clonal interference on the evolving population struc-
ture and highlights the complex dynamics present in an evolv-
ing population.
Since evolving populations are likely to be heterogeneous, it
is also possible that there are interactions between different
mutants within the population similar to mutual and/or com-
mensal interactions that occur between communities of organ-
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isms growing within the host. These types of interactions have
been observed in vitro in a long-term adaptive-evolution ex-
periment with Escherichia coli under glucose limitation (26),
where adaptive mutants that exhibit cross-feeding of different
metabolites establish a stable coexistence. In this scenario, the
increase in fitness of the adaptive mutant in the evolving en-
vironment would not be detected in the pairwise competition
experiments used to study fitness relationships. Thus, we can-
not rule out the possibility that complex interactions also con-
tributed to some of the observed expansions in the populations
that evolved here.
Relationship between the fluconazole MIC and relative fit-
ness coefficients. The MIC of an antifungal agent is an impor-
tant indicator of drug susceptibility (reviewed by White et al.
[41]). However, the relationship between the MIC value of a
pathogen and its ability to adapt to the environment is not
linear either in vivo or in vitro (7, 25). The short-term adaptive-
evolution experiments reported here for a continuous-culture
system support the idea that the MIC alone does not predict
the relative fitness of a strain in the presence of drug. Further-
more, for the majority of the adaptive clones isolated, there
was no fitness cost associated with increases in the fluconazole
MIC, which is consistent with other studies of in vitro-evolved
isolates (35). Similarly, no correlation between relative fitness
coefficients and MIC values was detected in the adaptive
clones. For example, DP-2-M9 showed a significant increase in
fitness in the presence of drug relative to DP-2-M8, yet its MIC
was reduced relative to DP-2-M8 (Table 1). The different
growth conditions and methods of measurement most likely
explain these differences: the MIC was determined using Etest
strip assays, where cells were grown on RPMI 1640 agar plates;
fitness was determined by using pairwise competition experi-
ments in chemostats with YNB liquid medium containing flu-
conazole. Thus, our data support the idea that the MIC does
not provide a direct measure of competitive fitness (7).
Conclusions. The emergence of drug resistance in fungal
pathogens is dynamic. Time course samples collected from
patients undergoing antifungal treatments provide data on the
evolution of pathogens in vivo. However, due to the limited
number of clones isolated, the population dynamics during the
emergence of drug resistance in vivo has been difficult to
assess. In vitro evolution of multiple populations in parallel
provides a more controlled environment for the study of
population dynamics. However, traditional adaptive-evolu-
tion experiments do not follow evolutionary dynamics due to
the lack of real-time indications of when adaptive mutants
arise and expand in the population. We addressed this chal-
lenge using VERT with C. albicans isolates evolving in the
presence of fluconazole to isolate adaptive mutants in a more
systematic manner. Importantly, we detected an increase in the
frequency of adaptive events in the presence of the drug. Fur-
thermore, isolates from one of the fluconazole-exposed popu-
lations evolved a general increase in fitness compared to the
parental strain in the absence of the drug, suggesting that drug
resistance mechanisms do not always come with an obvious
fitness cost. In addition, these resistance mechanisms are stably
maintained for at least 30 generations in the absence of the
drug.
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